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Abstract 
Purpose: To determine the effect of oral capsule of saffron (a herbal medicine) on anxiety and quality of 
sleep of diabetic patients of a tertiary healthcare facility in Zabol, Iran in 2016.  
Methods: This was a quasi-experimental study on 50 diabetics of Zabol who met the inclusion criteria. 
Participants were randomly split into two groups (control and test). Anxiety and quality of sleep were 
evaluated by Spielberger Anxiety Inventory and Pittsburgh Sleep Quality Index (PSQI). Participants in 
the intervention group received a daily (between 12 noon and 2 pm) intake of 300 mg saffron capsule 
after lunch while those in the control group received a placebo daily for a similar duration. After a week, 
anxiety and sleep quality were assessed.   
Results: A significant difference in anxiety and quality of sleep prior to and after saffron oral capsule 
intake (p = 0.001) was observed. In the control group, anxiety and quality of sleep did not show any 
significant difference before and after intervention (p = 0.001).  
Conclusion: The results show that saffron capsule intake is effective in reducing anxiety and improving 
the quality of sleep among diabetic patients. Further studies are required to enhance saffron capsule 
formulation. 
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Quality of sleep and anxiety are the most 
important mental disorders in diabetic patients. 
More than 80 and 14 % of diabetics suffer from 
low quality of sleep and anxiety disorders 
respectively [1]. More than 6 % of adult 
population is affected by diabetes in developing 
countries. Today, there are over 230 million 
diabetics worldwide. The prevalence of diabetes 
is estimated to be 3 - 5 % and more than 90 % of 
diabetes is Type II [2]. In addition to some 
complications such as retinopathy, nephropathy, 
and neuropathy, diabetes creates many 
psychological and behavioral complications 
which widely affects the quality of life of the 
patients.  
 
Sleep is a highly dynamic and organized 
biological process considered an important part 
of life. The quantity of sleep is associated with 
the quality of social interaction. Disturbed sleep 
is considered an important sickness at every 
stage of life. Sleep is one of basic human needs 
which is essential to maintain energy, 
appearance, and physical well-being. Sleep also 
reduces anxiety and stress. Chemical Drugs as 
the first line treatment of mental disorders in 
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diabetics contribute with different complications 
[3]. Interest in natural therapies has increased 
greatly today in many countries. Different 
evidences showed saffron have preventive and 
therapeutic role in diabetic patients [4,5]. 
Considering the limitations of studies concerning 
the effect of saffron on anxiety and quality of 
sleep in human's samples and prevalence of 




This study was approved by the ethics committee 
of Zabol University of Medical Sciences (no. ID 
1394-21-2) and complied with EMEA guidelines 
[6].  This quasi-experimental study included 50 
patients referred to diabetic clinic teaching 
hospital during the period between January and 
March 2016 in Zabol city, southeast of Iran. 
Sample size selected as the sample using the 
Cochran formula, reliability coefficient of 95 % 
and accuracy of 0.07.  The inclusion criteria were 
oral intake of drug, lack of cognitive disorders, 
willingness to participate in the study, age 20-60, 
minimum one-year diabetes, being literate, lack 
of drug intake which are effective in anxiety, no 
stressful event during the past year. 
 
Data were collected in Zabol Diabetes Center. A 
10-minute face-to-face briefing was done for 
each of the participant in the center. Informed 
consent was taken for participating in the study. 
The participants were randomized in to two 
groups (intervention (25) and control (25). 
Demographic questionnaires were completed by 
the patients. First, anxiety and the quality of 
sleep were evaluated using research tools. Then, 
the intervention group was requested for daily 
intake of saffron oral capsule which contains 300 
mg saffron for a week. The capsules were 
administered between 12 noon and 2 pm, after 
lunch, once daily [7]. In the control group, 
placebo capsules, instead of saffron capsules, 
were taken for a week. A text message was sent 
to the participants by the researcher in order to 
remind. After a week, the researcher forwarded 
the questionnaires to the participants and 
patients filled them out.  
 
The patients were trained on activity participation 
in study by following instructions includes: little 
use of foods that affect anxiety and quality of 
sleep of participants. They were instructed to 
avoid such foods. We trained family members for 
confirmation that participants are following all the 
instructions.  
Data were collected using a questionnaire with 
three sections: 1. Demographic Questionnaire; 2. 
Spielberger Anxiety Inventory [8]; 3. Pittsburgh 
Sleep Quality Questionnaire [9]. Demographic 
questionnaire covers age, gender, duration of 
diabetes, marital status and education level. 
Spielberger Anxiety Inventory (SAI) has 20 items. 
The 20 items were scored on a one-to-four scale, 
ranging between 20 and 80. The subjects were 
split into three groups: Mild Anxiety (20 – 40), 
Medium Anxiety (41-60), and Severe Anxiety 
(61-80). Pittsburgh Sleep Quality Index evaluates 
the quality of sleep (subjective from the patient's 
perspective) and nocturnal and adequate sleep. 
The items were scored on a 4-option scale (no, 
once a week, twice a week, and three time a 
week). The questionnaire also investigated sleep 
latency of longer than 30 min, hypnotic drug 
intake, and night wakening due to frequent 
urination, shortness of breath, feeling cold and 
hot and wakening due to pain. The scores were 
converted into percentage. In order to determine 
the severity of sleep disorder, the scores were 
split into the following categories: 0-25: no sleep 
disorder; 26-50 mild sleep disorder; 51-75: 
medium sleep disorder; 76-100: severe sleep 
disorder. The reliability and validity for the two 
questionnaires (PSQI and SAI) were validated in 




The Statistical Package for Social Sciences 
(SPSS version. 22.0 for windows (SPSS Inc., 
Chicago, IL, USA) was used to analyze the data. 
The categorical variables were compared using 
unpaired Student’s t-test and ANOVA. 





Most participants were male (56 %), married (96 
%) and had a master degree (30 %). On 
average, the duration of diabetes was 6 years. 
Mean age was 37 ± 2.1 (years).  Prior to 
intervention, 30 patients (60 %) (20 in 
Experimental group and 10 in control group) 
suffered from relatively severe anxiety. Twenty 
patients (40%) (5 in intervention group and 15 in 
control group) suffered from severe anxiety. The 
mean score of anxiety was 63.3 in experimental 
group showing relatively severe or severe 
anxiety. In control group, the mean score of 
anxiety was 60 to 74 (mean: 68). The mean 
scores were between 60 and 74, indicating the 
fact that the patients in control group had 
moderate or severe anxiety.  
 
After the intervention, the mean score of anxiety 
was 25.8 in experimental group, showing mild 
anxiety. The anxiety scores were between 20 
and 37, indicating moderate to low anxiety. The 
mean score of anxiety was 56.4 in control group  
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Table 1: Mean scores of anxiety prior to and after intervention in experiment and control 
 
Group Mean score Score range P-value 
Saffron   Prior to Intervention 63.3 60-74  
0.001 After Intervention 25.8 20-37 
Control  Prior to Intervention 63.4 60-74  
0.067 After Intervention 56.4 45-62 
  
   Table 2:  Quality of sleep in both groups before and after intervention 
 














N 0 19 0 0 
% 0 38 0 0 
Mild sleep 
disorder (1) 
N 2 6 2 1 
% 4 12 4 2 
Medium sleep 
disorder (2) 
N 14 0 9 8 
% 28 0 18 16 
Severe sleep 
disorder (3) 
N 9 0 14 16 
% 18 0 28 32 
P-value 0.002 0.091 
after a week, showing relatively severe anxiety 
and the scores ranged between 45 and 62, 
indicating moderate to high anxiety. In general, a 
significant difference was found prior to and after 
intervention concerning anxiety using unpaired 
Student’s t test (p = 0.001).  However, no 
significant difference was found in control group 
prior to and after placebo (Table 1). No 
significant difference was found concerning 
anxiety in both groups before intervention (p = 
0.067) using unpaired independent sample t-test. 
 
Prior to intervention, 46 %( 23) of patients had 
severe sleep disorder, 46 %( 23) had medium 
sleep disorder, and 8 %( 4) had mild sleep 
disorder in all participants. After intervention, 19 
patients (38%) had no sleep disorder and 6 
patients (12%) had mild sleep disorder in the 
experiment group. In the control group after 
intervention, a patient (2%) had mild sleep 
disorder, 8 (16%) had medium sleep disorder, 
and 16 (32%) had severe sleep disorder. 
Comparing the quality of sleep in both groups 
before and after intervention using paired sample 
t-test showed that a significant difference was 
found between the quality of sleep in intervention 
group before and after saffron oral capsule intake 
(p=0.002). No significant difference was found 
concerning the quality of sleep in control group 
prior to and after intervention (p=0.091) (Table 
2). 
 
Anxiety and quality of sleep were compared in 
control (56.4±11.4) and experimental groups 
(25.8±4.6) after intervention using paired sample 
t-test (Table 3). The results showed that a 
significant difference was found concerning 
anxiety in both groups after intervention 
(p=0.001). A significant difference was also 
found in terms of quality of sleep in both groups 
(p=0.01), showing that saffron oral capsule 
improved the quality of sleep of diabetics. 
 
Table 3: Quality of sleep in control and saffron groups 
after intervention 
 
Sleep disorder Saffron Control 
No (%) No (%) 
No sleep disorder  19(38) 0(0) 
Mild sleep disorder 6(12) 1(2) 
Medium sleep disorder 0(0) 8(16) 
Severe sleep disorder  0(0) 16(32) 




The results of study showed a significant effect of 
Saffron on quality of sleep   and anxiety in 
diabetic patients.  In traditional medicine, saffron 
is used as antispasmodic, sedative, digestive, 
anti-flatulence, diaphoretic, expectorant, sexual 
stimulant, increase of appetite, depression, renal 
colic, anti-inflammatory, analgesic. However, 
extensive review of scientific literature did not 
reveal adequate research on the effect of saffron 
capsules or its other products on anxiety and 
sleep quality in diabetic patients.  
 
Most of the researches on saffron efficacy have 
been conducted using animal models; therefore, 
further studies with diabetic patient’s subjects are 
necessary. Miladjerdi et al found that saffron 
reduced anxiety and increased sleep time in 
mice which are consistent with the findings of the 
present study [11]. Hosseinzadeh reported 
anxiolytic and hypnotic effects of saffron on 
anxiety and insomnia in mice [12]. Different 
studies in human subjects shown that saffron 
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reduced sleep disorders in postmenopausal 
women [13], anxiety in pregnant women [14], 
during the active phase of labor in pregnant 
woman [15].  
 
Potential candidates for the treatment of anxiety 
disorders and schizophrenia, anxiety and fatigue 
during the first stage of labor [16]. The results of 
these studies are consistent with present study. 
Anxiety is one of the factors closely associated 
with pain, and pain is also one of the causes of 
anxiety in patients [17]. Considering these facts, 
it could be concluded that pain relief is 
significantly effective in reducing anxiety. 
Analgesic effects of saffron have been identified 
in different studies [7,18]. The results were 
consistent with the present study, proving the 
effect of saffron on reducing the anxiety of 
human subjects. The effects of saffron on anxiety 
and the quality of sleep of diabetics are likely to 
be associated with the Crocin and safranal of 
saffron [19]. Crocin is a water-soluble compound 
and safranal is a fat-soluble one, acting by two 
different mechanisms. Crocin is likely to be 
effective in dopaminergic system and 
norepinephrine reuptake inhibition and safranal 
in serotonergic system. Saffron has similar 
activity to diazepam. Similar to diazepam as a 
benzodiazepine, it has anxiolytic, analgesic, and 
sleeping effects [20]. 
 
Limitations of the study 
 
This study had some limitations: (1) Small 
sample size. (2) Lack of prior research studies on 
the topic. (3) Any subject who did not observe 
the communication arrangements were replaced 




The findings of the study that oral saffron 
capsules significantly reduces anxiety and 
improves quality of sleep of diabetic patients. 
Thus, saffron may be useful as a useful adjuvant 
therapy for the management of anxiety and sleep 
disorders but further clinical studies, including its 
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